About
Helix is an enterprise-grade genomics platform purpose-built to integrate genomic intelligence into healthcare delivery, payer operations, and pharmaceutical research. The platform enables organizations to implement precision medicine at scale by translating genetic insights into practical health strategies that improve patient care and optimize operational efficiency. Helix's product suite includes the Helix Research Network (HRN), a collaborative ecosystem accelerating genomic discoveries across health systems; Helix Precision Pathway, which enhances clinical decision-making with advanced genomic insights; Helix Clinical Genomics, offering comprehensive diagnostic testing to simplify genetic analysis for providers and patients; Helix Genomic Advantage, designed to help health plans shift the cost curve by identifying high-risk populations; and GenoSphere, which provides curated, longitudinal clinico-genomic cohorts to support drug discovery, clinical trial optimization, and precision medicine innovation. Built around a proprietary Exome+® assay and the 'Sequence Once, Query Often' model, Helix allows healthcare organizations to continuously extract value from genomic data without re-sequencing. The platform is designed for enterprise scalability, supporting health systems in diversifying revenue streams through personalized health programs, targeted screenings, and value-based care models. Helix serves a broad ecosystem spanning health systems, life sciences companies, payers, and providers, driving transformative impact across the full healthcare continuum.
Key Features
- Helix Research Network (HRN): A collaborative network of 15+ health system members pooling genomic intelligence to accelerate discoveries and drive real-world clinical impact in precision medicine.
- GenoSphere Clinico-Genomic Cohorts: Curated, longitudinal datasets linking clinical and genomic data to enhance drug discovery, streamline clinical trial design, and support precision medicine research.
- Precision Pathway for Clinical Decision Support: AI-driven genomic insights integrated into clinical workflows to enhance provider decision-making and enable personalized care delivery at scale.
- Genomic Advantage for Health Plans: Genomic risk stratification tools that help payers identify high-risk populations, reduce unnecessary interventions, and improve member outcomes while lowering healthcare spend.
- Exome+® Assay & Sequence Once, Query Often: Proprietary sequencing technology and data model enabling organizations to continuously extract new clinical and research value from a single genomic sequence.
Use Cases
- Health systems launching population genomics programs to provide hereditary disease insights and preventive care recommendations to patients across large geographic regions.
- Pharmaceutical and biotech companies accessing real-world clinico-genomic cohorts via GenoSphere to identify drug targets and optimize clinical trial recruitment.
- Healthcare providers leveraging Helix Precision Pathway to incorporate genomic insights into routine clinical workflows for more personalized treatment decisions.
- Health plans implementing Helix Genomic Advantage to stratify member risk, reduce avoidable hospitalizations, and manage total cost of care through genomic intelligence.
- Academic and industry researchers partnering with the Helix Research Network to conduct large-scale genomic studies with diverse, longitudinal patient datasets.
Pros
- Massive Diverse Patient Dataset: Over 1.5 million diverse patients committed across the Helix Research Network, providing statistically powerful and representative genomic data for research and clinical programs.
- End-to-End Enterprise Platform: Covers the full spectrum from clinical diagnostics to population health management, drug discovery, and payer cost optimization — all within one integrated genomics ecosystem.
- Proven Health System Partnerships: Established partnerships with leading health systems such as HealthPartners demonstrate real-world deployability and enterprise credibility.
Cons
- Enterprise-Only Focus: Helix's platform is designed exclusively for large health systems, payers, and life science organizations — not accessible or relevant to individual consumers or small clinics.
- Complex Implementation Requirements: Integrating genomics into existing clinical and operational workflows requires significant organizational commitment, technical infrastructure, and change management.
- Opaque Pricing: No public pricing is available; costs are negotiated on an enterprise contract basis, making budget assessment difficult without a formal sales engagement.
Frequently Asked Questions
What is the Helix enterprise genomics platform?
Helix is an end-to-end genomics platform that helps health systems, payers, and life science companies integrate genomic data into clinical care, population health programs, and pharmaceutical research. It provides tools for diagnostics, clinical decision support, cohort research, and cost management.
What is GenoSphere and how does it support drug discovery?
GenoSphere is Helix's solution for accessing curated, longitudinal clinico-genomic cohorts. Pharma and biotech companies use it to enhance drug target identification, enrich clinical trial populations, and accelerate precision medicine development with real-world evidence.
What is the Helix Research Network (HRN)?
The HRN is a collaborative network of 15+ health system members that share genomic intelligence to advance research. Members gain access to large-scale, diverse genomic datasets that power population-level discoveries and drive real-world clinical impact.
How does Helix help health plans reduce costs?
Through Helix Genomic Advantage, health plans can use genomic risk stratification to identify members at elevated risk for costly conditions. This enables targeted, preventive interventions that reduce unnecessary treatments and improve long-term member outcomes.
What is the Exome+® assay and what makes it unique?
The Exome+® is Helix's proprietary sequencing assay that captures comprehensive genomic data in a single test. Combined with the 'Sequence Once, Query Often' model, organizations can continuously re-query the same genomic data as new clinical questions and research needs emerge — maximizing long-term ROI from each sequencing event.
